<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452578</url>
  </required_header>
  <id_info>
    <org_study_id>5190371</org_study_id>
    <nct_id>NCT04452578</nct_id>
  </id_info>
  <brief_title>Hepatitis C Virus (HVC) Positive Heart Grafts in HCV Negative Recipients</brief_title>
  <official_title>Pilot Investigation Using HCV Positive Heart Grafts in HCV Negative or Previously Successfully Treated Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor
      grafts in HCV negative heart recipients who are currently listed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Survival Rate</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Experimental: Recipient of HCV positive heart graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Procedure: Heart Transplantation</intervention_name>
    <description>A HCV negative or previously successfully treated recipient with a HCV positive graft.</description>
    <arm_group_label>Experimental: Recipient of HCV positive heart graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18 and older

          -  Active on the transplant list

          -  Donor organ with Antibody and NAT (nucleic acid test) positive for HCV

          -  HCV negative recipient; this includes patients who never had HCV and those with HCV
             previously eradicated with antiviral therapy. The latter is defined as those with
             undetectable HCV viral load at least 3 months since stopping therapy.

          -  Willing and able to provide written informed consent or for those subjects where
             hepatic encephalopathy affects their ability to provide initial or ongoing consent,
             has an appropriate and legally-authorized representative willing and able to provide
             consent on behalf of the subject

          -  Patients listed for multiple organ transplant (heart and kidney or heart and liver)
             can be included based on agreement of non-cardiac organ transplant team

        Exclusion Criteria:

          -  Participants co-infected with HIV

          -  Donor previously treated with an NS5a containing regimen (if treatment history of
             donor known)

          -  Known allergies or hypersensitivity to DAA or ribavarin

          -  Pregnancy and/or actively breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dmitry Abramov, MD</last_name>
    <phone>9095588184</phone>
    <email>dabramov@llu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loma Linda University Transplant Institute</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Abramov, MD</last_name>
      <phone>909-558-8184</phone>
      <email>dabramov@llu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Dmirty Abramov</investigator_full_name>
    <investigator_title>Assistant Professor, Loma Linda Medical Center</investigator_title>
  </responsible_party>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

